| Literature DB >> 32010490 |
Yu-Qing Ni1, Xiao Lin1, Jun-Kun Zhan1, You-Shuo Liu1.
Abstract
Aging is a progressive loss of physiological integrity and functionality process which increases susceptibility and mortality to diseases. Vascular aging is a specific type of organic aging. The structure and function changes of endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are the main cause of vascular aging, which could influence the threshold, process, and severity of vascular related diseases. Accumulating evidences demonstrate that exosomes serve as novel intercellular information communicator between cell to cell by delivering variety biologically active cargos, especially exosomal non-coding RNAs (ncRNAs), which are associated with most of aging-related biological and functional disorders. In this review, we will summerize the emerging roles and mechanisms of exosomal ncRNAs in vascular aging and vascular aging related diseases, focusing on the role of exosomal miRNAs and lncRNAs in regulating the functions of ECs and VSMCs. Moreover, the relationship between the ECs and VSMCs linked by exosomes, the potential diagnostic and therapeutic application of exosomes in vascular aging and the clinical evaluation and treatment of vascular aging and vascular aging related diseases will also be discussed. Copyright:Entities:
Keywords: endothelial cells; exosomes; vascular aging; vascular diseases; vascular smooth muscle cells
Year: 2020 PMID: 32010490 PMCID: PMC6961769 DOI: 10.14336/AD.2019.0402
Source DB: PubMed Journal: Aging Dis ISSN: 2152-5250 Impact factor: 6.745
Exosomal non-coding RNAs implicated in ECs functions.
| Exosomal non-coding RNAs | Cargos | Targets | ECs functions | Reference |
|---|---|---|---|---|
| Exosomal miRNAs | miR-122-5p | HGF | pro-proliferation, pro-migration | [ |
| miR-210-3p | HGF | pro-proliferation, pro-migration | [ | |
| miR-296-5p | HGF | pro-proliferation, pro-migration | [ | |
| miR-376c-3p | HGF | pro-proliferation, pro-migration | [ | |
| miR-214 | ATM | pro-proliferation, anti-senescence, pro-angiogenesis | [ | |
| miR-17 | ANGPT1 | pro-proliferation, pro-migration, | [ | |
| miR-19 | ANGPT1 | pro-proliferation, pro-migration | [ | |
| miR-20a | ANGPT1 | pro-proliferation, pro-migration | [ | |
| miR-30c | ANGPT1 | pro-proliferation, pro-migration | [ | |
| miR-126 | ANGPT1 | pro-proliferation, pro-migration | [ | |
| miR-92a | SOCS5 | anti- proliferation, pro-inflammation | [ | |
| miR-21 | RhoB | anti- proliferation, pro-inflammation | [ | |
| miR-24 | Sp1 | anti- proliferation | [ | |
| miR-15a | VEGF, NF-kB | pro-inflammation | [ | |
| miR-27a | VEGF, EGFR | pro-inflammation | [ | |
| miR-34a | BCL2, SIRT1 | pro-inflammation | [ | |
| miR-223 | ICAM-1 | anti-inflammation | [ | |
| miR-125a | DLL4 | pro-angiogenesis | [ | |
| miR-181b-5p | TRPM7 | pro-angiogenesis | [ | |
| miR-106b-5p | ANG2 | anti- angiogenesis | [ | |
| miR-320 | IGF-1, Hsp20, Ets2 | anti- angiogenesis | [ | |
| Exosomal lncRNAs | HOTTIP | cyclin D1, PCNA | pro-proliferation, pro-migration | [ |
| POU3F3 | bFGF, VEGF | pro-proliferation, pro-migration, | [ | |
| MALAT1 | IL-6, TNF-α, SAA3 | anti- proliferation, pro-migration, | [ | |
| HOTAIR | VEGF | pro-angiogenesis | [ | |
| H19 | Unknown | pro-angiogenesis | [ | |
| CCAT2 | TGFβ, Bcl-2 | pro-angiogenesis, anti-apoptosis | [ | |
| Meg3 | Unknown | anti- angiogenesis | [ | |
| GAS5 | P53, Caspase 3, Caspase 7 | pro-apoptosis | [ |
HGF: hepatocyte growth factor; ATM: ataxia telangiectasia mutated; ANGPT1: angiopoietin-1; STAT3: signal transducer and activator of transcription 3; SOCS5: suppressor of cytokine signaling 5; RhoB: ras homologue family member B; Sp1: specificity protein 1; VEGF: vascular endothelial growth factor; NF-kB: nuclear factor-kappa B; EGFR epidermal growth factor receptor; BCL2: B-cell CLL/lymphoma 2; SIRT1: silent information regulator 1; ICAM-1: intercellular adhesion molecule-1; DLL4: delta-like 4; TRPM7: transient receptor potential melastatin 7; ANG2: Angiopoietin 2; IGF-1: insulin-like growth factor-1; Hsp20: small heat-shock protein 20; Ets2: E26 transformation-specific 2; PCNA: proliferating cell nuclear antigen; bFGF: basic fibroblast growth factor; IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; SAA3: serum amyloid antigen 3;TGFβ:transforming growth factor β.
Exosomal non-coding RNAs implicated in VSMCs functions.
| Exosomal non-coding RNAs | Cargos | Targets | ECs functions | Reference |
|---|---|---|---|---|
| Exosomal miRNAs | miR-31 | MAPK/ERK, LATS2 | promote phenotype transition | [ |
| miR-133 | Sp1 | promote phenotype transition | [ | |
| miR-223 | MEF2C, RhoB | promote phenotype transition | [ | |
| miR-26a | Smad1 | inhibit phenotype transition | [ | |
| miR-21 | BCL2 | pro-proliferation | [ | |
| miR-130a | BMP2, TGFβ1 | pro-proliferation | [ | |
| miR-221/222 | p27, p57 | pro-proliferation | [ | |
| miR-152 | DNMT1 | anti-proliferation | [ | |
| miR-155 | Ets1 | anti-proliferation | [ | |
| miR-223 | PDGFRβ | anti-proliferation | [ | |
| miR-339 | PDGFRβ | anti-proliferation | [ | |
| miR-21 | PDGFRβ | anti-proliferation | [ | |
| miR-29b | DNMT3b | pro-migration | [ | |
| miR-143-3p | TGFβ | pro-migration, pro-angiogenesis | [ | |
| miR-712 | NCKX4 | pro-calcification | [ | |
| miR-714 | PMCA1 | pro-calcification | [ | |
| miR-762 | NCX1 | pro-calcification | [ | |
| miR-29a/b | ADAMTS-7 | anti-calcification | [ | |
| miR-125b | Ets1, Osterix | anti-transdifferentiation, | [ | |
| miR-126-3p | VEGF, ANG1, ANG2, MMP9, TSP1 | pro-angiogenesis | [ | |
| miR-92a | MKK4 | anti-apoptosis, anti-senescence | [ | |
| miR-34a | SIRT1 | pro-senescence | [ | |
| Exosomal lncRNAs | MALAT1 | Unknown | pro-proliferation, pro-migration | [ |
| MEG3 | p53 | anti-proliferation, anti-migration | [ | |
| lncRNA-p21 | p53 | anti-proliferation, pro-apoptosis | [ | |
| HOTAIR | anti-calcification | [ |
MAPK/ERK: mitogen-activated protein kinase/extracellular regulated kinase; LATS2: large tumor suppressor homolog 2; Sp1: specificity protein 1; MEF2C: myocyte enhancer factor-2c; RhoB: ras homologue family member B; Smad1: SMAD family member 1; BCL2: B-cell CLL/lymphoma 2; BMP2: bone morphogenetic protein 2; TGFβ1: transforming growth factor beta 1; DNMT1: DNA methyltransferase 1; Ets1: E26 transformation-specific 1; PDGFRβ: platelet-derived growth factor receptor-beta; DNMT3b: DNA methyltransferase 3b; TGFβ:transforming growth factor β; NCKX4: sodium/calcium exchanger 4; PMCA1: plasma membrane calcium ATPase 1; NCX1: sodium/calcium exchanger 1; ADAMTS-7: a disintegrin and metalloproteinase with thrombospondin motifs-7; VEGF: vascular endothelial growth factor; ANG1: angiopoietin 1; ANG2: angiopoietin 2; MMP9: matrix metallopeptidase 9; TSP1: thrombospondin 1; MKK4: mitogen-activated protein kinase 4; SIRT1: silent information regulator 1; ALPL: alkaline phosphatase; BMP2: bone morphogenetic Protein 2.
Figure 1.The communication between ECs and VSMCs via exosomal ncRNAs. The blue and brown arrows indicate that exosomal miR206 and miR-143/145 secreted by ECs regulate the functions of VSMCs. The green and purple arrows indicate that exosomal miR-155 and miR-143 secreted by VSMCs regulate the functions of ECs.
Roles of exosomal miRNAs in vascular aging related diseases.
| Cargo | Disease | Functions | ||
|---|---|---|---|---|
| Heart Diseases | miR-221/222 | CAD | Promote the progression of CAD | [ |
| miR-208a | CAD | Promote the progression of CAD | [ | |
| miR-126 | CAD | Inhibit the progression of CAD | [ | |
| miR-17-92 | CAD | Inhibit the progression of CAD | [ | |
| miR-22 | AMI | Protect against CMCs apoptosis | [ | |
| miR-133 | AMI | Promote the progression of AMI | [ | |
| miR-21 | AMI, HF | Promote CMCs loss | [ | |
| miR-24 | HF | Promote the progression of HF | [ | |
| miR-214 | HF | Promote the progression of HF | [ | |
| Hypertension | miR-211 | EH | Activate the axis of RAAS | [ |
| miR-615 | EH | Activate the axis of RAAS | [ | |
| miR-155 | EH | Regulate the progression of VC | [ | |
| Cerebrovascular Diseases | miR-126 | AIS | Inhibit microglial activation and inflammatory response | [ |
| miR-30d-5p | AIS | Inhibit autophagy-mediated microglial polarization to M1 | [ | |
| miR-181b-5p | AIS | promoted BMEC angiogenesis | [ | |
| miR-146a | VCID | Inhibit inflammatory effects on damaged astrocytes | [ | |
| Kidney Diseases | miR-200b | CKD | Regulate the progression of renal fibrosis | [ |
| miR-16 | CKD | Regulate the progression of CKD | [ | |
| PAD | miR-92a | Hind Limb Ischemia | Inhibit functional recovery | [ |
CAD: coronary artery disease; AMI: acute myocardial infarction; CMCs: cardiomyocytes; HF: heart failure; VC: vascular calcification; EH: essential hypertension; RAAS: rennin-angiotensin-aldosterone system; AIS: acute ischemic stroke; BMEC: brain microvascular endothelial cell; VCID: vascular cognitive impairment and dementia; CKD: chronic kidney disease; PAD: peripheral artery disease.